Clinical Trials

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

66 enrolled

Pancreatic Neoplasms

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

50 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04241276 2026-01-07

STARPAC2

170 enrolled

Pancreatic Neoplasms

NCT04831320 2025-12-30

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

328 enrolled

Pancreatic Neoplasms

NCT05630183 2025-11-13

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

81 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

468 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04481204 2025-10-09

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT04940286 2025-10-08

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

13 enrolled

Pancreatic Neoplasms

NCT01463072 2025-07-28

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

40 enrolled 17 charts

Breast Neoplasms

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Pancreatic Neoplasms

NCT02632305 2025-06-26

AX-CSARC

45 enrolled

Unresectable Biliary Tract Cancer

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

29 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02340117 2025-05-30

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

28 enrolled

Pancreatic Neoplasms

NCT05632328 2025-05-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

24 enrolled

Pancreatic Neoplasms

NCT06390059 2025-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

84 enrolled

Pancreatic Neoplasms

NCT01525966 2025-03-03

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

67 enrolled 12 charts

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02752685 2025-01-29

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

70 enrolled 7 charts

Breast Neoplasms

NCT06119217 2024-12-04

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

194 enrolled

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT04672005 2024-05-16

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

77 enrolled

Pancreatic Neoplasms

NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

216 enrolled